Bluejay Diagnostics, Inc.(BJDX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.2M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BJDX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Bluejay Diagnostics, Inc. (BJDX), a Healthcare sector company. BJDX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Bluejay Diagnostics, Inc. reports net income of $-1.9M, free cash flow of $-1.6M. Top institutional holders of BJDX by reported 13-F value include SABBY MANAGEMENT,, GEODE CAPITAL MANAGEMENT,, Tower Research Capital (TRC), based on the most recent SEC filings. BJDX trades on the Nasdaq exchange and files with the SEC under CIK 1704287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BJDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bluejay Diagnostics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-1.9M
Free Cash Flow
Q1 2026
$-1.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+22.5% YoYOperating Income
+30.5% YoYEPS (Diluted)
+78.0% YoYTotal Assets
+36.7% YoYOp. Cash Flow
+5.9% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|
| Revenue | — | — | $249.0K | — |
| Net Income | $-7.7M +22.5% | $-10.0M -7.1% | $-9.3M -702.6% | $-1.2M |
| Operating Income | $-7.2M +30.5% | $-10.3M -10.7% | $-9.3M -678.8% | $-1.2M |
| EPS (Diluted) | $-456.75 +78.0% | $-2075.13 -22406.8% | $-9.22 | — |
| Total Assets | $6.7M +36.7% | $4.9M -64.0% | $13.5M +791.1% | $1.5M |
| Operating Cash Flow | $-7.8M +5.9% | $-8.3M -7.4% | $-7.7M -1421.8% | $-508.7K |
AI Insight: BJDX Financial Trends
Bluejay Diagnostics shows persistent quarterly losses of $1-2M with equity declining from $9M to $4M over two years.
• Net losses remained consistently between $1M-$2M per quarter across all eight quarters from Q2 2024 to Q1 2026.
• Equity declined 56% from $9M in Q2 2024 to $4M in Q1 2026, indicating cash burn.
• Operating cash flow improved slightly from $-2M in early quarters to $-1M in recent periods.
⚠ Equity dropped back to $4M in Q1 2026 after temporary recovery to $6M in Q4 2025.
⚠ Revenue data remains unavailable across all quarters, limiting visibility into business progress.
AI Insight: BJDX Ratio Trends
Bluejay Diagnostics remains deeply unprofitable with ROE deteriorating from -82.7% in Q3 2024 to -183.6% in Q1 2026.
• ROE worsened from -82.7% in Q3 2024 to -183.6% in Q1 2026, showing persistent losses.
• ROA declined from -71.0% in Q3 2024 to -80.3% in Q4 2025, indicating deteriorating asset efficiency.
• ROIC fell from -76.0% in Q3 2024 to -97.9% in Q4 2025, reflecting poor capital allocation.
⚠ Missing operating margin and net profit margin data limits visibility into operational efficiency trends.
⚠ Debt-to-equity ratio unavailable across all periods, obscuring leverage assessment for cash-burning company.
Get alerted when BJDX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Bluejay Diagnostics, Inc. including:
Top Institutional Holders of BJDX
SABBY MANAGEMENT, LLC
$52.9K28,726 shGEODE CAPITAL MANAGEMENT, LLC
$51.8K28,127 shTower Research Capital LLC (TRC)
$3.2K1,729 shUBS Group AG
$228.00124 shL1 Global Manager Pty Ltd
$220.00120 shCaitong International Asset Management Co., Ltd
$6.003 sh
| Fund | Value | Shares |
|---|---|---|
| SABBY MANAGEMENT, LLC | $52.9K | 28,726 |
| GEODE CAPITAL MANAGEMENT, LLC | $51.8K | 28,127 |
| Tower Research Capital LLC (TRC) | $3.2K | 1,729 |
| UBS Group AG | $228.00 | 124 |
| L1 Global Manager Pty Ltd | $220.00 | 120 |
| Caitong International Asset Management Co., Ltd | $6.00 | 3 |
More Healthcare Companies
View all Healthcare →Put BJDX on your watchlist
Track score changes the day Bluejay Diagnostics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BJDX a good stock to buy?
13F Pro's AI-powered analysis of Bluejay Diagnostics, Inc. (BJDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BJDX are available on the BJDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BJDX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BJDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bluejay Diagnostics, Inc.'s investment landscape.